It’s been said that fear travels faster than the virus.
This is true. Given that Ebola is less contagious than many other communicable diseases, it’s easier to catch Ebola panic than Ebola itself. But if you’re a health care journalist writing about Ebola or the Ebola response, it’s sometimes hard to tell the real stories from the sensationalism.
In light of the Ebola diagnosis of two Dallas health care workers and the CDC initially placing blame on a “breach in protocol,” the past couple of days have seen a flurry of inflammatory Ebola coverage that focuses on the negatives. One of these is a survey from National Nurses United, the largest nurses’ union in the U.S.: 80 percent of NNU nurses surveyed don’t feel they have received adequate Ebola training. New allegations have surfaced that nurses treating him “worked for days without proper protective gear and faced constantly changing protocols.” Additionally, there have been federal funding cuts to public health preparedness and response activities: $1 billion less in FY 2013 than in FY 2002, a year in which the nation dealt with 9/11 and the anthrax attacks, and anticipated the SARS epidemic of 2003. Continue reading
When Thomas Eric Duncan died Wednesday of Ebola at Texas Health Presbyterian Hospital in Dallas, one of many questions that remained unanswered was why the hospital didn’t do more to diagnose and treat Duncan initially. On Sept. 25, Duncan walked into the hospital’s emergency room, was given antibiotics and sent home, according to coverage in the Los Angeles Times and elsewhere.
The question about what happened on Sept. 25 is important because Duncan could have infected many other individuals between when he was sent home on Sept. 25 and when he returned on Sept. 28 and was put into isolation. Writing in The New York Times, Manny Fernandez and Dave Philipps suggest that Duncan might still be alive if he had been admitted on Sept. 25.
After his death, Duncan’s fiancée, Louise Troh, and other African-Americans, questioned whether Duncan had received substandard care. Continue reading
Earlier today it was announced that Thomas Eric Duncan died in Dallas. Duncan, a Liberian national who contracted Ebola in Liberia, did not show symptoms on his journey to Dallas or immediately after his arrival. Various news outlets are reporting that travelers arriving in the United States from West Africa would have their temperatures taken and be asked to answer questionnaires ascertaining any possible exposure.
Given today’s events, it’s understandable that Internet speculation and media coverage have fanned the flames of public panic regarding Ebola. But reporters should be asking state and local epidemiologists if that panic is really justified.
Math can answer that question.
Some words are so familiar that it’s easy to assume you know what they mean – especially terms for a patient’s condition. Words such as “stable” and “critical” make it into health news all the time, but what do they really mean?
In light of the African Ebola epidemic, and the first diagnosis of Ebola on American soil, reporters should understand terms commonly used to describe a patient’s medical state or condition.
First, health writers should understand “vital signs” and what providers mean when they refer to vital signs as being normal. According to Medline Plus, “vital signs” include heart beat, breathing rate, temperature and blood pressure. Continue reading
What I’m reading about Ebola today:
“Possible second Ebola case in Dallas,” which may, of course, be related to “Experts question two-day delay in admitting Texas Ebola patient.” And now we learn that the “Ebola patient told hospital he had been to Liberia,” as well make use of a helpful interactive graphic on how contact tracing works. (Edited to add that last link.)
BioWorld Today has compiled a list of resources and stories about Ebola: “Special Report: The Push to Contain Ebola Virus.”
The World Health Organization has a page for Ebola situation assessments that it says will be updated Wednesday afternoon with information about a clinical trial of a vaccine. Continue reading